Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Anti-angiogenic therapies (AATs) are used to treat different types of cancers. However, their
success is limited owing to insufficient efficacy and resistance. Recently, single-cell omics …

Background The insulin-like growth factor family of ligands (IGF-I, IGF-II, and insulin),
receptors (IGF-IR, M6P/IGF-IIR, and insulin receptor [IR]), and IGF-binding proteins (IGFBP-1 …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict.
Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype …

The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular …

Nanoparticulate albumin bound paclitaxel (nab-paclitaxel, nab-PTX) is among the most
widely prescribed nanomedicines in clinical use, yet it remains unclear how nanoformulation …

Despite a strong preclinical rationale for targeting the insulin-like growth factor (IGF) axis in
cancer, clinical studies of IGF-1 receptor (IGF-1R)-targeted monotherapies have been …

Insulin-like growth factor (IGF) signaling is fundamental for growth and survival. A large body
of evidence (laboratory, epidemiological, and clinical) implicates the exploitation of this …